CDK4 and breast carcinoma: In a recent study, intrinsic resistance to Palbociclib was linked to a lysosomal gene signature in luminal ER+ breast cancer, suggesting that in some ER+ breast cancer cells, the lysosome sequesters CDK4/6 inhibitors, as demonstrated for TNBC cells [77].